The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-29. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Originally a Russian production, all in Russian with subtitles, produced by Maciej Drygas 15 October High Anxiety, about lifts and the required extensive technology of tall office buildings; Canary Wharf Tower (One Canada Square) had 50 floors with 36 lifts, which could travel up to 13.5 mph; Jim Fortune of Lerch Bates; novelist Philip Kerr; Otis Elevators alarm response centre of Farmington, Connecticut, which dealt with trapped passengers - it took about 20 minutes to rescue people; the Otis Test Tower, at Bristol in Connecticut, which had 29 floors and 11 lifts; architect Ken Yeang of Malaysia, known for his tall buildings; Gary Faltin of Otis; in the distant past, due to ropes, only goods were carried by lifts; in 1853 Elisha Otis invented a safety system for lifts, via a governor cable; only once have steel lift cables snapped, on 28 July 1945, in the 1945 Empire State Building B-25 crash after being lost in fog, severing the lift governor cable; if the cable snapped, due to the lift being balanced only after about nine people were in a lift, the lift would go upwards; on 12 August 1995, in the Empire State Building, a lift did go upwards, to be trapped at the 80th floor; the Woolworth Building, with 57 floors and 26 lifts, which could travel up to 10 mph - it was the world's tallest building from 1911 to 1930; engineer William Sheeran of Otis; medical doctor Rollin Stott, of the Linear Motion Laboratory of the Defence Research Agency (DERA) Centre for Human Sciences in north-east Hampshire; the feelings in the stomach, often sensed in a lift, comes from a pulse of adrenaline; Convent of Sacred Heart, with six floors; Nicole Fenchel was phobic of lifts; Doreen Powell of White Plains Hospital; the express lift, for the observation platform, in Tower 2 of the former World Trade Center had a journey time of 58 seconds; the former WTC had the world's second and third tallest office buildings; Tower 1 had 110 floors, being 417 metres high, with 96 lifts that could travel up to 15 mph; 70,000 people worked in the former WTC; people should not have to wait for a lift for no more than 30 seconds; Roger Howkins of Arup in London; 200 Vesey Street, known as Three World Financial Center, with 51 floors and 39 lifts, that could travel up to 14 mph; the former WTC was the first building to introduce the sky lobby design, with interspersed lifts; Robert DiChiara, assistant director of the former WTC; engineer Bruce Powell of Otis; Argentine architect, César Pelli, who designed One Canada Square of Canary Wharf; control systems of lifts anticipated demand; but there was a dark and menacing side to travel by lifts - Detectives Kevin Dineen and Lisa McClean of the NYPD Elevator Squad, at Carver Houses in the East Village, Manhattan, and how criminals could isolate victims; local youths and children would travel on top of the elevators for momentary thrills; the New York Marriott Marquis hotel, with 49 floors and 12 elevators, which could travel up to 15 mph; the Petronas Towers in Malaysia, with 88 floors, and 76 lifts, that could travel up to 16 mph, to be completed by 1997; lift ropes could go up to 600 metres, at the extreme most; new lifts would be powered by tubular linear motors or AC induction motors; 600 lifts with these new motors were operating in Japan; Yebisu Garden Place in Ebisu, Shibuya in Tokyo, where linear motors powered the lift counterweight; the Nishi-Shinjuku district in Shinjuku, Tokyo; many tall buildings were being built in Japan; Riverside Sumida Center, of Tokyo, built in 1994; the Yokohama Landmark Tower, with 70 floors, in Japan, built in 1993; Mitsubishi Electric had the world's fastest lifts, up to 28 mph; Junichi Sato of Mitsubishi, who said that he thought that Japanese people valued well-made products, and only trusted manufacturers too, whereas he thought that Americans and Europeans merely wanted functional products, whether good or not; the proposed enormous 800 metre Millennium Tower (Tokyo) for Tokyo Bay, with 150 floors, which was never built, but the Gherkin (30 St Mary Axe) was built instead; architect Andrew Miller of Foster Asia; there were twenty buildings over 60 floors being built; the Chinese economy was growing by 15% per year, and was Mitsubishi's biggest customer; the Century Tower (Tokyo), built in 1991, with 21 floors, with 14 lifts, that could travel up to 11 mph; lift technology had allowed Western business to prosper, but now it was superfluous for Western business. Narrated by Paul McGann, produced by Elizabeth Allen, directed by Gary Johnstone, made by Diverse Productions 22 October DNA in the Dock, an Equinox Special that was an update on the Incredible Evidence episode on 28 December 1994; The murder of 15-year-old Claire Hood, last seen on 19 January 1995, where 2,100 men had their DNA tested; her body was found in Cath Cobb Woods the next day; Sir Alec Jeffreys claimed that he could tell anyone apart; Timothy Wilson Spencer was the first person to be executed, with DNA evidence, on 27 April 1994, having committed murder in 1988; DCI Stuart Lewis, who worked on the Claire Hood investigation, who believed that her killer lived nearby - her killer lived 100 yards away; the United Kingdom National DNA Database began earlier in 1995, and in six months, 60,000 DNA specimens were recorded, and the database was intended to have 5 million specimens; an investigation of Orchid Cellmark, part of ICI, found that errors in correlation of specimens were made; California police gave test specimens to Cellmark, and errors were found, which Cellmark attributed to cross-contamination; Donald Findlay and a Scottish rape investigation in Largs, North Ayrshire, in 1987; former policeman Brian Kelly, and his wrongful conviction, for six years, serving four of them, for rape on 30 November 1989, through DNA evidence alone - DNA testing would later change in 1990, where crime scene DNA specimens were kept apart; Kary Mullis, who invented the PCR test in 1983, receiving the 1993 Nobel Prize in Chemistry, and knew about errors in DNA genetic testing; David Werrett of the Forensic Science Service, who set up the UK national DNA database in Birmingham, which deployed the PCR method - the more reliable Second Generation Multiplex Plus would be later introduced in 1999; Don Dovaston, later the deputy chief of Derbyshire Constabulary, which was the first police force to identify suspects through the UK DNA database; the Metropolitan Police had its own DNA database; Larry Mueller, population geneticist at the UCI School of Biological Sciences. Produced by David Poyser, directed by Hilary Lawson, made by TVF 5 November Kaboom!, the explosives engineer Sidney Alford; Controlled Demolition, Inc., founded by Jack Loizeaux; Rev Ron Lancaster, originally from Huddersfield, who founded Kimbolton Fireworks in 1964, when a chemistry teacher at Kimbolton School; in 1847 Ascanio Sobrero of Italy discovered nitroglycerin - nitroglycerin is the main component of dynamite; a detonation occurs at supersonic speed; Semtex was developed in Czechoslovakia in the 1960s; Ballistite, made from nitroglycerin and discovered in 1887, is the propellant for guns. Joint-production with NOVA and WGBH. Shown on Nova on 14 January 1997 12 November Avalanche, avalanches kill around two hundred people a year, with 120 of those in the Alps; Swiss physicist Othmar Buser of the Swiss Federal Institute for Forest, Snow and Landscape Research (WSL), who developed a database of avalanches; Bruce Tremper; Doug Fesler; powder snow avalanches can reach 150 mph; Laurent Buisson. Narrated by Heather Couper, made by Pioneer Productions with Discovery Networks 19 November God only Knows, about how some physicists see theology being explained through physics, such as Frank J. Tipler of Tulane University and his book The Physics of Immortality; George Johnson (writer) and book titles; Lewis Wolpert and how there was no evidence for God in the external world; David Finley of the National Radio Astronomy Observatory; religious writer Karen Armstrong, author of A History of God; Brazilian physicist Marcelo Gleiser; physicist Leon M. Lederman; Russell Stannard and physics before the big bang; the KTeV experiment at Fermilab, which looked at kaons, and Vivian O'Dell; Rev John Polkinghorne, former professor of Mathematical Physics at the University of Cambridge. Narrated by Bill Paterson, produced by Nicolas Kent, directed by Peter Webber 26 November Gloria's Toxic Death, about the death of Gloria Ramirez in California on 19 February 1994; a nurse, who took a blood sample from her, passed out from inhaling an unknown vapour coming from the blood sample; few episodes of Doctor Who had such a bizarre and unbelievable storyline; blood tests from the nurses revealed a lowering of the enzyme cholinesterase, which in other cases is linked to organophosphate poisoning; the Lawrence Livermore National Laboratory proposed a connection to dimethyl sulfoxide (DMSO) that had combined with oxygen given in the hospital to make dimethyl sulfate; the conditions of the hospital were repeated in a test, and the results underwent gas chromatography–mass spectrometry by Yolanda de Miguel at Department of Chemistry, Imperial College London. Narrated by Neil Pearson, directed by Tim Shawcross, produced by Geoff Deehan, made by Union Pictures with Discovery Communications 3 December On Jupiter, about the large gravitational effect that Jupiter has on the solar system; if the mass of Jupiter was thirty times bigger, the heat in its centre could sustain nuclear reactions, and it could become a star, maybe a brown dwarf; Gene Shoemaker of the Lowell Observatory and Palomar Observatory; Galileo Galilei discovered Jupiter's moons, Io, Europa, Ganymede (the largest moon in the solar system), and Callisto, on 7 January 1610; Heidi Hammel of MIT; Galileo (spacecraft), built at JPL and Ames in the 1980s, being planned to have launched in 1982, arrived at Jupiter on 7 December 1995; Torrence Johnson of JPL; Jim Scotti of the Spacewatch project at Kitt Peak National Observatory; Brian G. Marsden of the Central Bureau for Astronomical Telegrams; Vicki Meadows of the Anglo-Australian Telescope; Imke de Pater of the W. M. Keck Observatory on Mauna Kea; David Morrison (astrophysicist) of NASA Ames. Narrated by John Hurt, directed by Richard Smith, made by Pioneer Productions and the Discovery Channel 10 December Designing Dream Machines, about product innovation and product design of food processors and a reinvented motorbike by the Seymour-Powell design agency and its designer Nick Talbot, with the management team of Tefal UK and its managing director and a design by 43-year-old Dick Powell, and a possible new design of the ubiquitous 125CC BSA Bantam motorbike for MZ Motorrad- und Zweiradwerk of Germany by 42-year-old Richard Seymour; the 59 Club; Leigh Martin of the defunct Comet (closed in December 2012). Narrated by Marilyn Milgrom, directed by Richard Burke, produced by Richard Reisz. TV6 went on to make the six-part series Better by Design 17 December It Runs on Water, about the field commonly known as fringe science, where physicist Frank Close was sceptical if not broadly dismissive, stating that 300 years of science could not be overruled, but a professor of Aeronautics Paul Csysz of Saint Louis University mentioned that he thought some people in science were often unquestioning of their lifelong-held beliefs, and nervous of anyone trying to do so; an invention in Moscow was looked at by American physicist Harold E. Puthoff; Stanley Meyer's water fuel cell; NASA's propulsion research at Lewis Research Center in Cleveland, Ohio; it ends with Sir Arthur C. Clarke and Requiem (Mozart). Directed by Lawrence Simanowitz, produced and narrated by William Woollard, made by InCA Productions with Discovery Communications 20 December Do Vampire Bats have Friends?, an Equinox Special about whether animals have consciousness; zoologist Prof John Krebs, Baron Krebs, and whether animals had human-like sentience; biologist Gerald Wilkinson of the University of Maryland, and research, over five years, into relationships of vampire bats with other types of animals, and found food sharing between hungry vampire bats; zoologist Miriam Rothschild; psychologist Cecilia Heyes of UCL and self-perception of chimpanzees; zoologist Bernd Heinrich of the University of Vermont, and puzzle-solving of raven birds; zoologist Benjamin Beck of The National Zoo, and the apparent deployment of tools by animals; Ian Farquhar, and foxhunting, and whether foxes realise their predicament, and the Duke of Beaufort's Hunt in Gloucestershire; biologist Sir Patrick Bateson of the University of Cambridge, sensation of pain in animals, and the Animals (Scientific Procedures) Act 1986, which defined protected animals, that did not cover the octopus, but due to research by the Universities Federation for Animal Welfare (UFAW); Prof Peter Boyle and Martin Wells, and a 1993 amendment added the octopus; Prof Daniel Dennett of Tufts University, and how snakes think; psychologist Irene Pepper berg, of the University of Arizona, and an African Grey parrot called Alex, who has been talking for 18 years; the horse Clever Hans; Robert Seyfarth (scientist) and Dorothy Cheney (scientist), and their work on baboon warning calls and grunts, in Kenya. Narrated by Andrew Sachs, directed by Christopher Sykes, made by Christopher Sykes Productions
Certificate of Merit (1987) from the Indian Chemical Society for the best paper presentation, at the Convention of Chemists, 1987 2. Special Award and Citation (1988) of the Syndicate of Calicut University, Kerala, India for outstanding research contributions during 1985-1988 3. Swarnajayanti Research Grant (2001), Special research grant to outstanding young researchers by DST, Govt. India 4. Ramanna Fellow, DST (2007) 5. Adjunct Professor, Material Science Programme, IIT, Kanpur 6. Dean, Chemical Sciences, Academy of Scientific and Innovative Research (AcSIR) 7. A. V. Rama Rao Foundation Award Lecture of JNCASR, Bangalore (2012) 8. R. A. Mashelkar Endowment, NCL Pune (2012) 9. Chair on Nanoscience and Nanotechnology, Centre for Nanoscience and Nanotechnology, Mahatma Gandhi University, Kottayam, Kerala, 2013 10. Prof. K. K. M. Yusuff Endowment, Cochin University of Science and Technology, 2013 11. CHEMCON distinguished speaker award, 2016. 12. ISCB-2017 Award given by Indian Society of Chemists and Biologists. Academy Fellowships 1. Fellow, Indian Academy of Sciences, Bangalore (2006) 2. Fellow, National Academy of Sciences, Allahabad, India (2011) 3. Fellow, Indian National Science Academy, New Delhi (2012) 4. Honorary Fellow, Kerala Academy of Sciences (2013) 5. Fellow, Royal Society of Chemistry, London (2014) 6. Fellow, The World Academy of Science (2015) Research Fellowships
Minor pathways may be specific to certain parts of plants; these can be either identical to the vertebrate pathway (including the GLO enzyme), or start with inositol and get to ascorbic acid via l-galactonic acid to l-galactonolactone.
The pathophysiology of glaucoma is not well understood. Several theories exist regarding the mechanism of the damage to the optic nerve in glaucoma. The biomechanical theory hypothesizes that the retinal ganglion-cell axons (which form the optic nerve head and the retinal nerve fiber layer) are particularly susceptible to mechanical damage from increases in the intraocular pressure as they pass through pores at the lamina cribrosa. Thus, increases in intraocular pressure would cause nerve damage as seen in glaucoma. The vascular theory hypothesizes that a decreased blood supply to the retinal ganglion cells leads to nerve damage. This decrease in blood supply may be due to increasing intraocular pressures, and may also be due to systemic hypotension, vasospasm, or atherosclerosis. This is supported by evidence that those with low blood pressure, particularly low diastolic blood pressure, are at an increased risk of glaucoma. The primary neurodegeneration theory hypothesizes that a primary neurodegenerative process may be responsible for degeneration at the optic nerve head in glaucoma. This would be consistent with a possible mechanism of normal tension glaucoma (those with open-angle glaucoma with normal eye pressures) and is supported by evidence showing a correlation of glaucoma with Alzheimer's dementia and other causes of cognitive decline. Both experimental and clinical studies implicate that oxidative stress plays a role in the pathogenesis of open-angle glaucoma as well as in Alzheimer's disease.
Sources: en.wikipedia.org
== Production and composition == Dalbavancin is manufactured by fermentation of a selected Nonomuraea strain to generate the natural glycopeptide complex A-40926. This precursor is then selectively esterified at the carboxyl group of its sugar moiety, its peptidyl carboxyl group is amidated and the ester of the N-acylaminoglucuronic acid carboxyl group is saponified. The outcome is a compound mixture of two closely related structural families—A and B—that can be further subdivided into a total of five subtypes (see table below). At least ten different dalbavancin components have been described, of which the B0 component makes up around 80–98 wt%.
=== Protein effectiveness === Some have argued that there is little evidence to indicate any benefit to using bodybuilding protein or amino acid supplements. A 2005 overview concluded that "[i]n view of the lack of compelling evidence to the contrary, no additional dietary protein is suggested for healthy adults undertaking resistance or endurance exercise". In contrast, a 2018 systematic review, meta-analysis and meta-regression concluded that, “Dietary protein supplementation significantly enhanced changes in muscle strength and size during prolonged RET in healthy adults.“ (RET is an abbreviation for resistance exercise training.)
In 1986 and 1987, Transkei, a larger, wealthier, and more populous entity, undertook a series of military raids on Ciskei, and attempted to seize control of Ciskei. One of these raids was an attack on leader Lennox Sebe's compound, with the apparent goal of taking him hostage, in order to force a merger of the two Bantustans. Transkei had previously granted sanctuary to Lennox Sebe's estranged brother, Charles, the former head of Ciskei's security forces, who had been imprisoned in Ciskei on charges of sedition, in addition to previously kidnapping Lennox Sebe's son. The South African government ostensibly intervened to warn the Transkei government off. However, during a later meeting of the Truth and Reconciliation Commission, it was revealed that the plan to amalgamate the Transkei and Ciskei into a proposed Xhosaland, as well as the freeing of Charles Sebe from prison, had been carried out by South African security forces linked to the Civil Cooperation Bureau, in order to consolidate an anti-ANC front in the Eastern Cape region, as part of the abortive Operation Katzen.
Sources: en.wikipedia.org
For an odd-numbered saturated fat (Cn), 0.5 * n - 1.5 oxidations are necessary, and the final process yields 8 acetyl CoA and 1 propionyl CoA. It is then converted to a succinyl CoA by a carboxylation reaction and generates additional 5 ATP (1 ATP is consumed in carboxylation process generating a net of 4 ATP). In addition, two equivalents of ATP are lost during the activation of the fatty acid. Therefore, the total ATP yield can be stated as:
The new 20th district encompasses downtown San Antonio and extends eastward to its historically Black east side and the community of Kirby, as well as westward to Leon Valley and several neighborhoods north of Lackland AFB. The incumbent is Democrat Joaquin Castro, who was re-elected unopposed in 2024. Kamala Harris won the two-thirds Hispanic district with 63.5% of the vote and Colin Allred 66.6% in 2024.
The endocrine system consists of the principal endocrine glands: the pituitary, thyroid, adrenals, pancreas, parathyroids, and gonads, but nearly all organs and tissues produce specific endocrine hormones as well. The endocrine hormones serve as signals from one body system to another regarding an enormous array of conditions, resulting in variety of changes of function.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.